Purpose of review: Staphylococcus aureus (S. aureus) is correlated with the development of persistent severe inflammatory disease of the upper airway including chronic rhinosinusitis with nasal polyps (CRSwNP). The presence of S. aureus is associated with atopic disease including allergic rhinitis and atopic dermatitis and is associated with poor outcomes.
Background: Atopic dermatitis (AD) is a heterogeneous disease with a multifactorial aetiology and complex pathophysiology. This heterogeneity translates into different trajectories of disease progression with respect to severity, persistence and risk of development of atopic comorbidities.
Areas covered: The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. A systematic literature search was conducted, and publications were reviewed for applicable treatment guidelines.
Containing relevant Learning Zones, guidelines, trials and news.
LEO Pharma presented new clinical data from the ECZTRA 6 and ECZTEND trials of Adbry (tralokinumab-ldrm), marketed outside of the US under the tradename Adtralza, in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD). New data from the ECZTRA 6 trial showed that Adbry significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with AD after 16 weeks.
Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Regeneron Pharmaceuticals, Inc.and Sanofi announced that the European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy . With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.
Areas covered: This review summarizes the literature on the mechanism of action, clinical efficacy and safety of dupilumab, a monoclonal antibody that targets the α-subunit of the interleukin-4 receptor (IL-4Rα) leading to the inhibition of both the IL-4 and IL-13 pathways.
In recent years, the importance of the microbiome in maintaining healthy skin has become apparent. Both the classic microbiology cultivation techniques used since the early 1970s and the next-generation sequencing procedures refined...